HECTD1, a HECT domain-containing E3 ubiquitin ligase, plays a critical role in regulating protein ubiquitination and degradation, as well as various cellular processes such as cell cycle progression, cell migration, and differentiation. As a member of the HECT (homologous to E6AP carboxyl terminus) domain family, HECTD1 possesses a conserved catalytic domain responsible for transferring ubiquitin molecules onto substrate proteins, thereby marking them for degradation by the proteasome or regulating their cellular localization and function. The substrate specificity of HECTD1 is mediated by its interaction with specific adaptor proteins or substrate receptors, which facilitate the recognition and ubiquitination of target proteins. Through its ubiquitin ligase activity, HECTD1 controls the turnover of key regulatory proteins involved in signaling pathways and cellular processes, thereby exerting tight regulation over various aspects of cell physiology.
Strategies for inhibiting HECTD1 could involve disrupting its interaction with substrate proteins or adaptor molecules, thereby preventing the ubiquitination and subsequent degradation of target proteins. Additionally, targeting the catalytic domain of HECTD1 with small molecule inhibitors or peptides may interfere with its ability to transfer ubiquitin molecules onto substrate proteins, thereby inhibiting its ubiquitin ligase activity. Furthermore, modulating the expression levels or stability of HECTD1 through strategies such as RNA interference or protein degradation pathways may provide alternative approaches for inhibiting HECTD1-mediated ubiquitination and downstream signaling. Elucidating the precise mechanisms underlying HECTD1 inhibition will provide valuable insights into its physiological roles and implications in cellular homeostasis and disease pathogenesis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can lead to an accumulation of ubiquitinated proteins, potentially causing feedback inhibition of HECTD1 activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Another proteasome inhibitor, increases ubiquitinated protein levels, possibly leading to a reduction in HECTD1 activity due to feedback mechanisms. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
Inhibits NEDD8-activating enzyme, potentially affecting HECTD1 activity by altering neddylation processes related to ubiquitin ligases. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Inhibits ubiquitin activating enzyme E1, which could disrupt the ubiquitination process and indirectly affect HECTD1's function. | ||||||
NMS-873 | 1418013-75-8 | sc-478803 | 5 mg | $300.00 | ||
A p97/VCP inhibitor, impacts protein degradation pathways and may indirectly inhibit HECTD1 through altered ubiquitin-dependent processes. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Proteasome inhibitor that could lead to the accumulation of ubiquitinated proteins, potentially providing negative feedback to HECTD1 activity. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
A selective proteasome inhibitor, can cause an accumulation of ubiquitinated proteins, which might indirectly inhibit HECTD1. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $72.00 $145.00 $265.00 $489.00 $1399.00 $99.00 | 19 | |
A protease inhibitor that may affect protein degradation pathways, indirectly influencing HECTD1 activity. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
By inhibiting lysosomal function, it can affect protein degradation pathways, potentially impacting HECTD1 indirectly. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Inhibits vacuolar-type H+-ATPase, affecting lysosomal acidification and possibly indirectly inhibiting HECTD1. | ||||||